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Background: The Drugs for Neglected Diseases initiative (DNDi) is a not-for profit organization committed to
providing affordable medicines and access to treatments in resource-poor settings. Traditionally drug development
has happened “in house” within pharmaceutical companies, with research and development costs ultimately
recuperated through drug sales. The development of drugs for the treatment of neglected tropical diseases
requires a completely different model that goes beyond the scope of market-driven research and development.
Artesunate and mefloquine are well-established drugs for the treatment of uncomplicated malaria, with a strong
safety record based on many years of field-based studies and use. The administration of such artemisinin-based
combination therapy in a fixed-dose combination is expected to improve patient compliance and to reduce the
risk of emerging drug resistance.
Case description: DNDi developed an innovative approach to drug development, reliant on strong collaborations
with a wide range of partners from the commercial world, academia, government institutions and NGOs, each of
which had a specific role to play in the development of a fixed dose combination of artesunate and mefloquine.
Discussion and evaluation: DNDi undertook the development of a fixed-dose combination of artesunate with
mefloquine. Partnerships were formed across five continents, addressing formulation, control and production
through to clinical trials and product registration, resulting in a safe and efficacious fixed dose combination
treatment which is now available to treat patients in resource-poor settings. The south-south technology transfer of
production from Farmanguinhos/Fiocruz in Brazil to Cipla Ltd in India was the first of its kind. Of additional benefit
was the increased capacity within the knowledge base and infrastructure in developing countries.
Conclusions: This collaborative approach to drug development involving international partnerships and
independent funding mechanisms is a powerful new way to develop drugs for tropical diseases.
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The Drugs for Neglected Diseases initiative was foun-
ded in 2003 as a collaborative, patients’ needs-driven,
not-for-profit drug research and development (R&D)
organization in order to develop new or improved
treatments for neglected diseases, such as malaria, leish-
maniasis, human African trypanosomiasis and Chagas
disease. In 2011, DNDi extended its activities to include
projects on paediatric HIV and specific helminth
infections. It operates with an alternative model [1] from* Correspondence: jean-rene.kiechel@wanadoo.fr
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reproduction in any medium, provided the orthat utilized by the pharmaceutical industry, where re-
search and development is funded and mainly under-
taken in-house with the aim of producing a profitable
drug. As a product development partnership, DNDi’s
funding is provided by governments and charitable or
philanthropic organizations to develop much needed
anti-infectives of little commercial interest. The develop-
ment model is dependent upon strong collaborations
and partnerships worldwide, across academia, public
health institutes, and the biotechnology and pharma-
ceutical industries.td. This is an Open Access article distributed under the terms of the Creative
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that 3.3 billion people were at risk of malaria in 2010, of
which 1.2 billion living in the African and Southeast
Asian regions were at the highest risk. Approximately
81%, or 174 million (113–239 million) cases were in the
African region, with another 13% in the Southeast Asian
region; the vast majority (91%) of deaths occur in the
African region. Children under five years of age are the
worst affected, accounting for approximately 86% of
malaria deaths worldwide [2].
In the 1980s, there was a rise in resistance of malaria to
chloroquine in many parts of Southeast Asia and South
America, and emerging resistance along the east coast of
Africa which led to the recommendation by the WHO in
2001 [3] to abandon the use of chloroquine worldwide and
switch to using artemisinin-based combination therapy
(ACT) as first-line treatment for uncomplicated Plasmo-
dium falciparum malaria. Four different forms of ACT were
recommended by the WHO: artemether/lumefantrine,
artesunate + amodiaquine, artesunate + sulphadoxine/
pyrimethamine and artesunate + mefloquine (for areas of
low transmission).
Mefloquine (MQ) was originally discovered by the
Walter Reed Army Institute of Research. However, al-
though it was not covered by a patent, it was expensive
to produce, and there was little initial interest in its de-
velopment. The UNICEF-UNDP-World Bank-WHO
Special Programme for Research and Training in Trop-
ical Diseases (TDR) worked with the pharmaceutical
company Hoffmann-la-Roche to develop a cheaper syn-
thetic pathway, and sponsored more than 12 clinical
trials in Latin America, Zambia and Thailand, leading to
product registration in 1984 [4]. Initial successes in clin-
ical trials carried out in Bangkok showed efficacy against
multi-resistant P. falciparum [5], and in 1986 the com-
bination of MQ with sulphadoxine/pyrimethamine
(MSP) was 98% effective in treating 5,000 patients on
the Thai-Burmese border [6]. However, P. falciparum re-
sistance quickly developed, and in 1989 the MSP com-
bination was abandoned [7].
Artemisia, or Qinghaosu, is a traditional Chinese
herbal cure that has been used to treat malaria for over
a thousand years. Isolated from the leaves of Artemisia
annua (annual wormwood), it is a potent anti-malarial.
Modern day semi-synthetic analogues have improved its
solubility and absorption, and there are now a number
of artemisinin derivatives available, including the water-
soluble artesunate (AS), which forms part of the arsenal
of combination treatments for malaria [8]. Artemisinin
derivatives cause rapid clearance of parasites from the
blood and a speedy resolution of symptoms, but as they
are rapidly cleared from the system they are used in
combination with a slower acting drug that kills the
remaining parasites over three days of treatment.Thailand was the first country to implement an arte-
misinin combination therapy (ACT) regime, following
extensive use of MQ with AS along the Thai-Burma
border in the early 1990s [9-11], leading to its adoption
as national policy for the treatment of uncomplicated
malaria in 1994, which continues to this day. Given the
growing problem of delayed parasite clearance of P. fal-
ciparum malaria in Southeast Asia countries, indicative
of artemisinin-resistant malaria, with early evidence
confirmed at the Cambodia-Thailand border [12], WHO
took the unprecedented step of requesting pharmaceut-
ical companies to immediately halt the production of
single-drug, artemisinin-containing tablets in order to
protect this class of drugs [13]. Since 2006 WHO has
recommended the use of artemisinin-based combination
therapy to ensure high cure rates of falciparum malaria
and to reduce the spread of drug resistance [14].
A search for suitable combinations of existing malaria
drugs to control malaria resistance was carried out in
1998 by TDR, with support from the US Agency for
International Development (USAID) and the Wellcome
Trust. The resulting data analyses showed a combination
of AS and MQ to be a good clinical option in Latin
America and Southeast Asia. The WHO technical con-
sultation on anti-malarial drug combination therapy in
2001 [3] suggested producing a fixed dosage formulation
of ASMQ containing mefloquine at 8 mg/kg to be
administered daily over three days [15], in order to
optimize the use of co-formulations (AS+MQ). As there
was a clear public health need but a lack of research
groups willing to invest in its development, the Fixed-
dose Artesunate-based Combination Therapy (FACT)
consortium, born out of the initial partnership between
DNDi and TDR, undertook the development of ASMQ
(and AS plus amodiaquine) fixed-dose combinations
(FDC) [16,17]. FACT aimed to produce an affordable
and widely available FDC that could be available to treat
patients most affected by malaria whilst other potential
drugs were still in early development.
Case description
The FACT consortium was founded by DNDi and TDR
in 2002, and included the Brazilian government-owned
pharmaceutical company, Farmanguinhos/Fiocruz, the
Université Bordeaux Segalen, Universiti Sains Malaysia,
Mahidol University and the Shoklo Malaria Institute in
Thailand, the Centre National de Recherche et de For-
mation sur le Paludisme (CNRFP) in Burkina Faso and
the University of Oxford as core members. Partnerships
were set up with various industrial, academic, govern-
mental and non-governmental organizations who carried
out specific aspects of research, and an advisory commit-
tee made up of international experts met annually to ad-
vise and ensure all questions related to the worldwide
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FACT members also carried out specific research in the
development process.
Analytical and bio-analytical methods were developed
by Universiti Sains Malaysia and subsequently transferred
to Farmanguinhos/Fiocruz. Farmanguinhos performed the
preformulation and formulation work required to scale up
to industrial scale production. Quality control methods
were developed and validated. The Université Bordeaux
Segalen financed toxicology and genotoxicology studies
performed by Unitox and Genotox in Brazil.
Initial trials with the FDC were conducted by clinical
partners across Southeast Asia and Latin America.
A pioneer working relationship was developed with
Brazilian regulatory authorities, the Agencia Nacional de
Vigilancia Sanitaria (ANVISA), to prepare a dossier for
submission for drug registration in the country. Consult-
ation meetings were organized at different phases of the
development on the way to the submission of the regula-
tory dossier (2005–2008).
In order to make the drug more easily accessible in
Asia, a technology transfer agreement (2007–2009)
enabled the drug manufacturing process to be trans-
ferred from its original manufacturer’s, the government-
owned pharmaceutical company Farmanguinhos in Brazil,
to Cipla Ltd, a generic pharmaceutical company in India.
Cipla Ltd manufactured registration batches of the prod-
uct in 2009, and a prequalification dossier was submitted
to WHO in 2010, with members of the FACT team clari-
fying responses to enquiries.
Discussion and evaluation
Artesunate and mefloquine are well known treatments
for falciparum malaria in loose combination. Since 2001,
the ASMQ combination has been one of the WHO-
recommended forms of ACT for first-line treatment to
provide adequate cure-rates and delay the development
of resistance. DNDi and partners decided to improve
this therapy by developing a FDC of ASMQ, as the con-
venience afforded by reducing tablet numbers to once
daily over three days is expected to lead to increased pa-
tient compliance and adherence. Such an undertaking
required both pharmaceutical and industrial develop-
ment as well as clinical studies. The subsequent technol-
ogy transfer from Farmanguinhos, Brazil to Cipla Ltd,
India facilitated access in endemic regions of Asia.
Development of a FDC of ASMQ has depended on
close collaborations between industrial, academic, gov-
ernmental and NGO research organizations, involving
partnerships with and between developing countries,
with independent funding provided by both public (EU’s
INCODEV FP5, French AFD, Dutch DGIS, Spanish
AECID, Swiss SDC, UK DFID and the European
Commission’s EDCTP) and private (Médecins SansFrontières, MSF) sources. The global cost of the devel-
opment of ASMQ FDC, including pharmaceutical devel-
opment costs, clinical studies, technology transfer and
some implementation activities, is expected to amount
to approximately 15 million Euros. This figure does not
include in kind contributions by Farmanguinhos and
Cipla Ltd, who contributed to the industrialization of
the fixed dose combination.
Pharmaceutical and preclinical development
The Universiti Sains Malaysia developed analytical and bio-
analytical methods [18] for use in quality control and clinical
pharmacological studies. The analytical techniques were
transferred to Farmanguinhos/Fiocruz who formulated a
fixed-dose combination product with appropriate stability
and biopharmaceutical characteristics, together with a viable
manufacturing process and the required validated control
methods. Clinical batches were produced and toxicology,
bio-equivalence, bio-availability and pharmacokinetic studies
performed for inclusion in registration and prequalification
files.
Clinical development
Artesunate and MQ have been used in combination for
over 20 years, involving more than 38,000 patients in
91 studies in 22 countries across Southeast Asia, the
Western Pacific, Africa and Latin America [19]. The
fixed dose combination of these has been demonstrated
to be efficacious and safe for treating uncomplicated ma-
laria in more than 25,000 patients in Thailand, Myanmar,
India and in a large intervention study in Brazil (Table 1)
[20-26]. Of these, the safety and efficacy study carried
out on 500 patients in Thailand was pivotal, with effi-
cacy of the FDC comparable to that of the loose tab-
let combination, better toleration and a lower incidence of
vomiting. In addition, the Myanmar study (808 patients)
compared the effectiveness of the four ACT FDCs re-
commended by WHO at the time and showed the ASMQ
FDC to have the highest cure rate and the lowest rate of
gametocyte carriage, providing the greatest post-treatment
suppression of recurrent falciparum malaria and the most
effective suppression of blood-stage Plasmodium vivax
malaria [25].
Mefloquine has been associated with an increased inci-
dence of nausea, vomiting, dizziness, dysphoria and sleep
disturbance in clinical trials [27-47] and adverse reactions of
varying severity have been experienced by a number of
patients when taking AS and MQ in a loose combination or
the FDC, primarily in the first 28 days of treatment. How-
ever, WHO [14] notes that mefloquine-related adverse
effects are seldom debilitating and where this ACT has been
deployed it has been well tolerated. There were no serious
adverse effects reported in the Brazilian intervention study
involving more than 23,000 patients, including children,
Table 1 Key clinical studies
Country Study type Phase n Primary objective Major findings
Thailand HNV, PK and
tolerability
1 24 PK and bio-availability of AS and MQ;
administered separately and as a
coformulation to healthy volunteers and
patients
No difference was seen in the bio-equivalence of MQ in
the two formulations; although a difference was seen




2 50 Population PK model of new dosage regime
of MQ with AS in loose combination over
three days
Splitting the 25 mg/kg dose of MQ into three doses of
8 mg/kg improved oral bio-availability compared to the
conventional split-dose regimen results. New regimen




2b 50 Safety and PK of ASMQ FDC vs non-fixed AS
+MQ against multi-drug resistant falciparum
malaria in adults
FDC well-tolerated with broadly similar PK profiles to
non-fixed AS plus MQ [22]. The observed slowing of
heart rate was best explained by malaria resolution[23]
Efficacy and
safety
3 500 ASMQ FDC with separate tablets in adults and
children with uncomplicated multidrug-
resistant falciparum malaria
Cure rates were 91.9% for the FDC after 63 days, with a
lower incidence of vomiting compared to those in the
loose tablets group [24]
Myanmar Competitive
Effectiveness
4 808 Effectiveness of five artemisinin combination
regimens with or without PQ in
uncomplicated falciparum malaria
ASMQ provided the greatest post-treatment
suppression of malaria after 63 days, with the addition




3 77 PCR corrected cure rate of ASMQ FDC in adult
patients with uncomplicated falciparum
malaria





3b/4 23,845 Effectiveness of ASMQ FDC in reducing
malaria transmission in the Juruá valley
Early detection of malaria and treatment with ASMQ
FDC was feasible and efficacious, significantly reduced
the incidence and morbidity of falciparum malaria[26]
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ASMQ FDC was designed to provide an optimized, short-
term, gastro-intestinal tolerance, reducing the overall risk of
vomiting. The risk of increased neuropsychiatric reactions
following the use of MQ within 60 days of treatment
is not an issue in Southeast Asia, Western Pacific and
Latin America, areas with low to medium transmission.
The initial targeting of Southeast Asia and Latin America
was based on the low to middle intensity transmission and
multidrug resistance forms of malaria in these regions. Fur-
ther studies involving ASMQ FDC are now ongoing with a
number of partners in African countries (Figure 1; Table 2),
including children and pregnant women, and patients with
sickle cell anaemia, which will provide additional informa-
tion for areas with a different epidemiological profile. A
large-scale study in pregnant women is also ongoing in
Thailand. Children and pregnant women are among the
most vulnerable of those affected by malaria.
ASMQ FDC could also play a role within the strategy of
multiple first-line therapies to delay emergence and spread
of disease where, in areas of high transmission, repeat
treatments are likely to be necessary within 60 days of the
initial treatment. A recent model predicts that in areas with
high transmission, combining a gametocytocidal artemisinin
derivative with a longer-acting partner drug will protect
patients from re-infection and reduce transmission more ef-
fectively than some common currently used ACT regimens
which are gametocyte-killing but short-acting [48].Plasmodium vivax is the second most important spe-
cies causing human malaria, accounting for about 40%
of malaria cases worldwide [14]. It is the dominant mal-
aria species outside Africa, prevalent in endemic areas in
Asia, Central and South America, Middle East and
Oceania but rare in Africa. WHO recommends treating
uncomplicated vivax malaria with chloroquine in com-
bination with primaquine, where chloroquine is effective.
However, in areas of chloroquine resistance an appropri-
ate ACT (but not artesunate-sulphadoxine/pyrimeth-
amine) combined with primaquine is to be used,
particularly where ACT is first line therapy for P. falcip-
arum, although primaquine is counter-indicated with
severe glucose-6-phosphate dehydrogenase (G6PD) defi-
ciency. Experience indicates that it is likely that prima-
quine combined with ASMQ will result in high cure
rates against vivax blood stage infection and relapse [49].
In Brazil, the Tropical Pathology Research Institute
(IPEPATRO) is studying the efficacy of ASMQ FDC in
treating P. vivax malaria compared to chloroquine or
artemether-lumefantrine when each is administered with
primaquine.
Technology transfer
Within the FACT consortium, Farmanguinhos/Fiocruz
was the first manufacturer of ASMQ FDC. The technol-
ogy transfer of ASMQ FDC between Farmanguihos/





Figure 1 International partners involved in the development of ASMQ FDC. FACT Core Members: DNDi, TDR of WHO, Farmanguinhos/
Fiocruz (BR), Université Bordeaux Segalen (FR), Universiti Sains Malaysia (MY), Mahidol University (TH), Mahidol Oxford Tropical Medicine Research
Unit, Shoklo Malaria Research Unit (TH), Centre National de Recherche et de la Formation sur le Paludisme (CNRFP) (BF), University of Oxford (UK).
Preclinical Development: Universiti Sains Malaysia (MY), Farmanguinhos /Fiocruz (BR), Cipla Ltd (IN). Clinical Development: Southeast Asia:
University of Oxford (UK), Mahidol University (TH), Mahidol Oxford Tropical Medicine Research Unit (TH), University Sains Malaysia (MY), Shoklo
Malaria Research Unit (TH), Mae Sot Clinic (TH), Indian Council for Medical Research (IN), Médecins Sans Frontières, Medical Action Myanmar (MM);
Latin America: Amazon Network for the Surveillance of Anti-malarial Drug Resistance (RAVEDRA)/Ministry of Health (BR), National Malaria Control
Program Brazil; Africa: CNRFP (BF), Kenya Medical Research Institute (KEMRI) (KE), Institute of Tropical Medicine Anvers (BE), National Institute for
Malaria Research (TZ), Kwame Nkrumah University (GH), Centre Muraz (BF), University of Malawi (MW), Tropical Medicines Research Centre (ZM),
Royal Tropical Institute (KIT) (NL), Liverpool School of Tropical Medicine (UK), Ifakara Health Institute (TZ). Manufacturers: Farmanguinos/Fiocruz
(BR), Cipla Ltd (IN).
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Southeast Asia. There were some problems encountered
during this first-time process. A halt in the production
of MQ API by the original manufacturer led to signifi-
cant delays whilst a new manufacturer was identified
and the product evaluated. There were differences in the
particle size and flow compatibility of this replacement API
compared with the original product necessitating changes
to the manufacturing process, which required some time.
In addition, Cipla’s equipment differed from that used by
Farmanguinhos, requiring further modifications to the
process. However these improvements ultimately resulted
in faster tablet manufacture of ASMQ to GMP-standards.
With the resolution of these problems the transfer was
completed in 2010, and as such it is a prime example of a
successful south-south technology transfer.With Cipla Ltd in charge of manufacturing in Asia, to-
gether with Indian registration granted in November
2011, the supply of ASMQ in Asia and in other parts of
the world is ensured at pre-agreed prices [50].
Product registration and prequalification
DNDi worked with the Brazilian regulatory authorities,
the Agencia Nacional de Vigilancia Sanitaria (ANVISA),
in order to register ASMQ FDC for use in the country.
In late 2006, a new piece of Brazilian registration
incorporated an expedited review process for the drugs
to treat neglected diseases. ASMQ FDC was granted
Brazilian registration approval in March 2008 and
adopted as treatment policy by the Ministry of Health as
an alternative to first-line treatment for uncomplicated
P. falciparum malaria [51].
Table 2 Ongoing clinical studies
Country Study type Phase n Primary objective
Nigeria Sickle cell proguanil vs AS+MQ
vs SP+AQ
1/2 270 Safety and tolerability of bi-monthly intermittent preventive treatment with
AS+MQ or sulphadoxine-pyrimethamine + amodiaquine compared to
proguanil for prevention of malaria and related complications in patients
with sickle cell anaemia
Amazon Basin Efficacy 2/3 100 Evaluate the effectiveness of ASMQ FDC to treat uncomplicated falciparum
malaria in the Juruá Valley
Burkina Faso Pregnant women 2/3 48 PK of ASMQ FDC in pregnant women
Burkina Faso, Ghana,
Malawi and Zambia
Pregnant women: ASMQ vs
DHA-PQ vs ASAQ vs AL
3 3500 Efficacy and safety of four ACTs (artemether-lumefantrine, amodiaquine-
artesunate, mefloquine-artesunate and dihydroartemisinin-piperaquine)
in pregnant women with P. falciparum malaria
Tanzania, Burkina
Faso and Kenya
Efficacy, safety and PK in
children ASMQ vs AL
4 940 Efficacy, safety and population pharmacokinetics ASMQ FDC in African
children vs artemether-lumefantrine
Thailand Pregnant women: ASMQ vs
DHA-PQ vs AL
3 1,000 Randomized trial of three ACT for malaria in pregnancy (DMA)
Brazil Efficacy and safety P. vivax:
ASMQ+PQ vs CQ+PQ vs AL
+PQ
3 264 Efficacy and safety for treating P. vivax: ASMQ+PQ vs CQ+PQ vs AL+PQ
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ceutical Control Bureau of the Ministry of Health
approved the use of ASMQ FDC for the treatment of
acute uncomplicated malaria resulting either from P. fal-
ciparum mono-infection or mixed infections with P.
vivax. This approval is a step for ASMQ FDC within the
ASEAN (Association of Southeast Asian Nations)
Harmonization Scheme between health authorities, and
as Malaysia is a Pharmaceutical Inspection Convention
country, it should facilitate registration in the other
countries. DNDi is coordinating the review of ASMQ
with ASEAN regulatory authorities to obtain drug regis-
tration, which will in turn lead to adoption by malaria
control programmes. The registration of ASMQ FDC is
underway in countries in Southeast Asia and the Western
Pacific where AS+MQ is part of a national policy for
uncomplicated malaria [52].
WHO pre-qualified the Cipla ASMQ FDC product in
September 2012. This recognition of a high-quality
product will enable procurement agencies to bulk-buy
goods for use in resource-poor settings. A recent ana-
lysis found that a large percentage of anti-malarial drugs
in Asia and sub-Saharan Africa are either fake or of in-
ferior quality, leading to vulnerable populations receiving
poor treatment and adding to the threat of resistance
developing [53].
Working with a virtual model
The DNDi model works through collaboration and co-
operation between international partners from a wide
range of research settings. As such it has required the
management of collaborators spread over different re-
search centres across Europe, USA, Asia, South America
and Africa. This has led to management problems not
necessarily encountered in a conventional industrialsetting, notably in terms of communication between the
various project groups. Bi-annual project meetings were
held in order to communicate results effectively between
all project partners, interspersed with local research
group meetings held at the relevant sites. This dispersal
of knowledge and personnel meant that it took one to
two years before a team could be sufficiently well
established to work together efficiently and effectively,
and adaptation to differing political and cultural
influences was required. However, the overall belief in
the value of the project, together with a desire to suc-
ceed, was highly motivating for all involved, and much
was achieved.
This virtual model gave rise to some complications
which would have been simpler to resolve in a trad-
itional pharmaceutical setting, based on existing infra-
structure and know-how. For example, in addition to
those problems described above relating to the produc-
tion of mefloquine API, another change of manufacturer
had to be managed very late in development due to a
halt in production of artesunate API by the selected sup-
plier. It was essential to demonstrate the identity of the
new API selected and its GMP status, as well as ensur-
ing the Drug Master File (DMF) acceptability by regula-
tory authorities and WHO. In both cases, as the FACT
partnership did not represent a potential big customer
this made negotiations more difficult and required good
will from the suppliers, who became, to some extent,
members of the partnership. These API changes had an
impact on the development and registration timelines. A
further complication was more typical of those
experienced by international organizations. The partner
in Brazil, Farmanguinhos, developed the FDC according
to local specifications, or to the specification in force in
production. This required vigilance and adaptation, with
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cessary in order for the manufactured product to fulfill
development and quality specifications for worldwide
use.
Finally, working with a number of different partners
magnified the effects of natural turnover in personnel, at
different levels. There was occasionally a risk of lack of
continuity in vision which required a prolongation of
project management beyond the initial years of early de-
velopment, and the sustained support from the executive
level management of the participating partners.
Capacity building
Partnerships have been set up with and between
developing countries, where there has been the added
benefit of building capacity of resources and knowledge
in countries in South America, Southeast Asia and
Africa. This in turn may lead to increased product uptake,
and to local scientists and pharmaceutical firms pursuing
follow-on innovations that could address local access
issues [54].
Farmanguinhos/Fiocruz has acquired much useful
knowledge and experience in its involvement with the
project. ASMQ FDC was the first new product fully
developed by the company, taking it through from devel-
opment of the manufacturing and control processes, val-
idation of control methods and manufacturing
processes, industrial scale up and production, compil-
ation of the regulatory file and on to successful product
registration in Brazil. One employee received training in
the preparation of the analytical methods related to AS
at Universiti Sains Malaysia. This knowledge was passed
on to Farmanguinhos/Fiocruz, as an enabling step in the
control of the production process and product develop-
ment. Other members of the Brazilian development
team received training in toxicology studies.
During the course of this project, team members at
the University Sains Malaysia learned how to perform
bio-analytical work under GLP conditions, and those
involved in clinical development acquired a better
understanding of the requirements in developing a drug
to ICH standards for regulatory approval. In India, staff
involved in clinical trials were trained to GCP standards,
including training in maintaining correct documentation
and the completion of case record forms.
Conclusions
Artesunate and MQ in combination have been adopted as
first-line treatment of uncomplicated malaria in several
countries in Southeast Asia (Cambodia, Malaysia, Thailand
and Myanmar) and South America (Bolivia, Peru, Brazil and
Venezuela) [52]. In Brazil, where ASMQ FDC is produced
by the government-owned pharmaceutical company
Farmanguinhos/Fiocruz, the government provides freetreatment to patients. Cipla Ltd has committed to making
their product available at pre-agreed, affordable prices.
DNDi and its partners are working towards lowering the
price of ASMQ in the future. The Medicines for Malaria
Venture (MMV) and DNDi have had a long-standing rela-
tionship, which ranges from reciprocal access to high-
throughput drug screening results through to joint support
of clinical studies. MMV has led a collaborative effort to de-
velop a low-cost process for MQ, together with Develop-
ment Chemicals Ltd and Creative Chemistry, UK-based
process chemistry specialists. As part of its work on
developing a single isomer of MQ [55], MMV has developed
a significantly cheaper manufacturing process, resulting in a
reduction in bulk drug from 1,100 USD/kg to 400 USD/kg.
The development of a semisynthetic artemisinin,
prepared from a dihydro-artemisinic acid (DHAA) pre-
cursor synthesized by Saccharomyces cerevisiae [56,57],
will be at the lower end of the AS pricing band, so en-
suring availability at an optimized cost.
The availability of low-cost versions of AS and MQ
will ultimately increase access to the FDC treatment.
Pragmatic strategies such as the Affordable Medicines
Facility for malaria (AMFm) to subsidize anti-malarials
and demand forecasting (PAHO Strategic Fund) should
also facilitate access to ACT at affordable prices.
With several quality-assured types of ACT available in
the market and very promising combinations in the
pipeline, more efforts should be made to use all the
available tools towards better control and elimination of
malaria.
DNDi was set up as a not-for-profit organization in 2003
in order to address the pressing need for effective treatments
for patients with the most neglected tropical diseases, as one
of the first Public Private Partnerships (now known as Prod-
uct Development Partnerships). The development of a FDC
of ASMQ was one of its initial projects, and the lessons
learnt have had an impact on its approach to drug develop-
ment which will be applied to the management of other
diseases across its portfolio and will require new and differ-
ent partners according to the development stage of
the candidate drugs. Following the successful development
of two treatments for malaria (ASMQ and artesunate-
amodiaquine), DNDi will finalize the transfer of its mal-
aria treatments to partners by 2014, in line with its
recently revised business plan.
This collaborative approach to drug development enabled
by independent funding mechanisms and involving partners
from across the globe and from a variety of research
settings, is a powerful new way to develop drugs for tropical
diseases, so making new treatments available to patients in
resource-poor settings.
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